Home / Peptides
Tirzepatide — weight loss

Tirzepatide

Tirzepatide

Also called: Mounjaro, Zepbound

By The Health Stacks Research TeamUpdated July 28, 2026

Tirzepatide is a special medicine that acts like two different hormones in the body at the same time. It is often used by people who need help managing their weight or blood sugar levels. This medicine is usually given as a shot once a week. It works by talking to the brain and the stomach to help control how hungry a person feels. It is a strong tool that doctors may prescribe for certain health problems related to metabolism.The main reason people use this medicine is to help them lose weight and keep their sugar levels steady.

It works by copying natural hormones that tell the body it is full. This can make a person want to eat less food. When the body does not need as much food, it starts to use stored fat for energy instead. This process can lead to significant weight loss over time. It also helps the body handle sugar better, which is very important for staying healthy.While this medicine shows promise, it is still being studied to see all the ways it helps the body.

Some research suggests it might also help the heart, but scientists are still checking this information. It is important to know that this medicine can cause side effects like feeling sick to the stomach. You should only use this medicine if a doctor says it is safe for you. It is not a magic fix, but it can be a helpful part of a health plan.

Research-stageEarly-stage — studied in cell or animal models, not yet tested in humans. Verified confidence80–100 — backed by strong, well-corroborated sources (peer-reviewed research, clinical guidelines). Our highest confidence tier.
Where to Source Tirzepatide
Tested purity COA available Fast shipping

What Tirzepatide Helps With

The benefits people report — backed by research.

Glycemic & metabolic (95)

Helps regulate blood sugar 95/100· 14 srcGlycemic control 95/100· 5 srcType 2 diabetes treatment 90/100· 5 srcGlycemic control in Type 2 Diabetes 95/100· 3 srcDiabetes treatment 90/100· 3 srcType 2 Diabetes Management 90/100· 3 srcGlycaemic control in Type 2 Diabetes 95/100· 2 srcReduction of blood glucose 95/100· 2 srcGlycaemic control 95/100· 2 srcMetabolic improvement 95/100· 2 srcGLP-1 receptor activation 90/100· 2 srcReduced glucagon secretion 85/100· 2 srcReductions in glycated hemoglobin 85/100· 2 srcTreatment of type 2 diabetes 72/100· 2 srcPrevention of B12 Deficiency 60/100· 2 srcImproves clinical outcomes in Type 2 Diabetes Mellitus 95/100Treatment of hyperglycemia in diabetes 95/100GIP and GLP-1 receptor agonism 95/100Boosts blood flow to injuries 95/100Dual hormone action 95/100Reduction of HbA1c 95/100Glycaemic control superior to existing GLP-1 agonists 95/100Improved glycemic control and reduced HbA1c 95/100Dual agonist action on GLP-1 and GIP receptors 95/100HbA1c reduction 95/100Improves blood glucose levels in adults with T2D 95/100A1c Reduction 95/100Tirzepatide dual-incretin recomposition 95/100A1c Reduction in Type 2 Diabetes 95/100Dual GIP/GLP-1 receptor agonism for enhanced metabolic effects 95/100Activates GLP-1 and GIP receptors simultaneously 95/100Glycemic improvement 95/100Fasting serum glucose reduction 95/100Glycemic control in Hispanic/Latino patients 95/100Glycaemic efficacy 95/100Superior HbA1c reductions compared to semaglutide 95/100Tirzepatide superior to Semaglutide in head-to-head trial 95/100Reduced odds of new-onset retinopathy in individuals without baseline diabetic retinopathy 95/100Significant HbA1c reduction 95/100Management of Type 2 Diabetes Mellitus 90/100Treatment of Severe Hypertriglyceridemia 90/100Hormone secretion from human islets 90/100Reduction of Lipoprotein levels 90/100Achievement of normoglycaemia 90/100Suppresses glucagon release 90/100Restores normoglycemia in pre-diabetes 90/100Supports liver health 90/100Triglyceride and Lipid Improvements 90/100A1c reduction of 0.5-1.5% by week 12 90/100Effective for treating type 2 diabetes 90/100Tirzepatide acts as a novel dual GIP and GLP-1 receptor agonist for metabolic disease 90/100Superior Efficacy over Semaglutide 90/100Significant A1C reduction 90/100Reduction of risk of worsening kidney problems and kidney failure in Type 2 diabetes and chronic kidney disease 90/100Recommended as injectable therapy for further intensification of glycemic control after 3 to 4 oral therapies fail 90/100Dual GIP receptor and GLP-1 receptor agonist mechanism of action 90/100Lipid Profile Improvement 90/10094% reduction in risk of developing type 2 diabetes 90/100Reduction of HbA1c levels in type 2 diabetes 90/100Glucose regulation 90/100GIP receptor activation 90/100Improved HbA1c and fasting glucose 90/100Glucagonostatic response 90/100Notable improvements in glycemic control 88/100Anti-diabetic potential via GIP antagonism 85/100Decreases chances of heart attack, stroke, or other diabetes-related complications 85/100Metabolic rate increase via GH 85/100Improvements in cardiometabolic markers 85/100Targets multiple aspects of metabolic syndrome 85/100CagriSema dual-receptor combination 85/100Dasiglucagon is a next-generation ready-to-use glucagon analog for artificial pancreas pumps 85/100Dual GLP-1 and GIP receptor agonism achieves high rates of NASH resolution 85/100Contributes to lipid homeostasis 85/100Greater triglyceride reduction with tirzepatide 85/100Management of severe reactive hypoglycemia 85/100Stabilization of glucose profiles 85/100Reduction of hypoglycemic events 85/100Stabilization of glucose profiles and reduction of hypoglycemic events in reactive hypoglycemia 85/100Improved lipid metabolism 85/100Prevention/treatment of B12 deficiency 80/100Enhances BCAA clearance 75/100Regulates blood-sugar levels 72/100Antidiabetic benefits 72/100Tirzepatide activates both GLP-1 and GIP receptors 72/100Fasting glucose drops 5-15 mg/dL in weeks 2-4 72/100Activates GIP and GLP-1 receptors to regulate blood glucose 72/100Tirzepatide and Retatrutide activate GLP-1 and GIP pathways 72/100Dual GIP and GLP-1 receptor activation 72/100GIP receptor modulation 72/100Reductions in glycated hemoglobin in type 2 diabetes 72/100Methylation support 70/100Reduction in HbA1c in T1D patients 65/100Increased Time in Range for blood glucose 65/100Decreased Time Above Range 65/100Boosts energy 60/100

Weight management (78)

Supports weight loss 95/100· 37 srcHead-to-head comparisons favor tirzepatide at matched dosesAppetite suppression 85/100· 35 srcFat Loss & Recomp 95/100· 3 srcImproves sleep 90/100· 3 srcBoosts blood flow to injuries 95/100· 2 srcReduction in waist circumference 95/100· 2 srcReduction of appetite and food intake 90/100· 2 srcDual GIP/GLP-1 receptor agonism 90/100· 2 srcReduced appetite 90/100· 2 srcAppetite suppression via GLP-1 pathway 85/100· 2 srcAppetite reduction 72/100· 2 srcReduction of morbidity and mortality in obesity 95/100Correction of obesity and diabetes 95/100Boosts energy 95/100Appetite suppression via GLP-1 and GIP receptor activation 95/100Effective for the Treatment of Obesity 95/100Reduces appetite and suppresses hunger 95/100Fat reduction 95/100Appetite suppression via GIP and GLP-1 receptor activation 95/100Fat Mass Reduction 95/100Appetite-control consistency 95/100Reduction in waist-to-height ratio 95/100Reduction in fat mass 95/100Hypophagia 90/100Induces satiety 90/100Enhanced fullness/satiety via Amylin analog 90/100Appetite reduction and increased satiety 90/100Tirzepatide and semaglutide used in obesity with and without type 2 diabetes 90/100Improves BMI and suppresses appetite by mimicking GIP and GLP-1 hormones 90/100Orforglipron provides an oral GLP-1 treatment option for obesity 90/100GLP-1s represent a major clinical advancement 90/100Improves metabolic, mechanical, and mental health parameters in patients with excess adiposity 90/100Fat Loss 90/100Stronger satiety signaling via dual GLP-1/GIP mechanism compared to GLP-1 alone 90/100Appetite suppression via stronger satiety signaling from dual GLP-1/GIP mechanism 90/100Dual GLP-1/GIP receptor agonism produces synergistic effects on appetite, adipose tissue biology, and metabolic rate 90/100Endorsed as a rational option for hyperglycemia in T2D patients with obesity and OSA 90/100Decreases appetite and helps regulate how much you eat 90/100Reduces appetite and food intake 90/100Better GI tolerability per kg lost with tirzepatide 90/100Dual GIP and GLP-1 receptor agonism for type 2 diabetes and obesity management 90/100GIP Receptor Activation 90/100Treatment of obesity in Type 2 Diabetes 90/100Highly effective anti-obesity therapeutic 90/100Appetite suppression via central receptor activation 90/100Significant reductions in waist circumference 88/100Lipolysis enhancement via GH/IGF-1 85/100Central satiety signalling 85/100Reduction of Visceral Fat 85/100Treatment of Obesity Hypoventilation Syndrome 85/100Enhanced Lipid and Glucose Metabolism via Adipose Tissue Remodeling 85/100Appetite and Craving Regulation 85/100Body Composition Improvements 85/100Cost-effective versus semaglutide for obesity treatment 85/100Amycretin functions as a GLP-1/amylin co-agonist suitable for oral administration 85/100Petrelintide acts as a potent, stable, long-acting human amylin analog 85/100Reduces food noise 85/100Preferential improvement of body composition 85/100Appetite suppression and satiety 85/100Helps regulate blood sugar 85/100Suppresses appetite 85/100Brown Adipose Tissue Activation 85/100Appetite suppression via GLP-1 and GIP receptor agonism 85/100Preferential reduction of visceral adipose tissue 85/100Reduction of Visceral Adipose Tissue 85/100Tesofensine non-incretin appetite suppression 80/100Reduced Food Cravings 80/100Activates brown adipose tissue 80/100Potential synergy with estrogen to suppress appetite 80/100Estrogen may enhance the appetite-suppressing effects of GLP-1 medications 75/100Increases satiety and reduces appetite 72/100Appetite suppression and reduced cravings 72/100GLP-1 receptor agonism 72/100Treatment for Obesity 72/100Appetite regulation via hypothalamic signaling 70/100Tirzepatide shrinks obesity-linked breast tumors 65/100Reduced appetite and increased satiety 60/100Appetite suppression within 3-5 days of initial dose 60/100

Cardiovascular & vascular (26)

Boosts blood flow to injuries 95/100· 4 srcBlood Pressure Reduction 90/100· 3 srcCoronary atherosclerotic plaque regression 90/100Treatment of resistant hypertension 90/100Reduces cardiometabolic risk factors 90/100Reduces systolic blood pressure by 7-9 mmHg and lowers triglycerides by 22-28% 90/100Blood pressure normalization 90/100Lipid Profile and ASCVD Risk Improvement 90/100Improvement in lipid profiles 90/100Cardiometabolic signals 90/100Improved lipoprotein profiles 90/100Improvements in cardiometabolic parameters 90/100Reduction in systolic blood pressure 85/100Improvement in heart failure with preserved ejection fraction 85/100Reduction of pericardial and epicardial fat 85/100GIP and GLP1 reduce atherosclerosis in preclinical studies 85/100GIPR and GLP1R agonism provides cardiorenal protection 85/100Reduced blood pressure 85/100Comparable Systemic Exposure to Abdomen 85/100Treatment of Heart Failure with Preserved Ejection Fraction 85/100Anti-atherosclerotic effects 80/100Endothelial function improvement 80/100Reduces occurrence of repeat heart attacks and strokes in T2D patients 72/100Reduces risk of serious events like heart attack and stroke 72/100Reduces risk of heart failure 72/100Lipid parameter improvements 70/100

Renal & hepatic (14)

Supports liver health 95/100· 4 srcSlows eGFR decline 85/100· 2 srcReduces major kidney events compared to dulaglutide 72/100· 2 srcMASH resolution in 62% of patients at 52 weeks 95/100Kidney protection and slowed decline of eGFR 95/100Kidney outcome improvement 90/100Kidney Protection 88/100Slowed renal clearance and extended exposure via lipidation and albumin binding 85/100Reduction of major kidney events 85/100FE 201836 is a short-acting V2R agonist for treating nocturia 80/100Efruxifermin shows significant reductions in hepatic fat fraction 80/100Kidney protective effects 80/100Associated with sustained improvements in quality of life in CKD 72/100Reduces major kidney events 72/100

Neuroprotection & cognitive (14)

Supports brain health 90/100Reduces alcohol cravings and average number of drinks consumed 85/100Adjunct treatment for Opioid Use Disorder 80/100GIP and GLP1 are neuroprotective in preclinical models of neurodegenerative disease 80/100GLP-1 receptor agonists are under investigation for the treatment of Parkinson's disease 80/100Nerve regeneration and myelin protection 80/100Improved nerve conduction velocity 80/100GLP-1 agonists reduce alcohol cravings and rewarding effects of alcohol 75/100Reduction of 'food noise' 72/100Modulation of sympathetic/parasympathetic tone 70/100Neuroprotective Potential 70/100Potential efficacy in treating Cannabis Use Disorder 70/100Treatment of chronic low back pain 65/100Ketamine provides relief for treatment-resistant depression 60/100

Reproductive & hormonal (12)

Metabolic improvement in Polycystic Ovary Syndrome 95/100Endocrinology indications 90/100Treatment of idiopathic short stature 90/100Restoration of ovulatory cycles in women with PCOS 85/100Reduction of ovarian cysts in women with PCOS 85/100Gender-affirming hormone therapy 85/100Treatment of hypoparathyroidism 85/100Reproductive vitality and women's healthy ageing 85/100Elinzanetant treats moderate to severe hot flashes due to menopause 85/100Fertility-sparing treatment for Endometrial Cancer 80/100More regular menstrual cycles in PCOS/PMOS patients 75/100Estrogen amplifies GLP-1 metabolic effects 75/100

Antioxidant / oxidative stress (9)

Increased Fat Oxidation 90/100· 2 srcAttenuation of metabolic adaptation 90/100Increased glutathione synthesis 85/100Increases fat oxidation 85/100Reduction of oxidative stress in endothelial cells 85/100Glutathione production 85/100Hepatic lipid oxidation / Reduced hepatic steatosis 85/100Fat oxidation and metabolic flexibility via MOTS-C 75/100Boosts energy 70/100

Gastrointestinal & gut (8)

Heals gut issues 95/100· 5 srcIntestinal growth enhancement 95/100Reduces appetite and slows down digestion by mimicking GIP and GLP-1 hormones 90/100Reduces inflammation 85/100Consistent absorption in abdomen 85/100Reduced Nausea Compared to Abdomen 85/100Reduction of nausea 80/100Slows digestion to keep users feeling full longer 72/100

Musculoskeletal (8)

Improvement in psoriatic arthritis disease activity when treating obesity with tirzepatide alongside ixekizumab 90/100Speeds muscle recovery 90/100Joint pain reduction and improved mobility 85/100Tirzepatide improves psoriatic arthritis outcomes when combined with ixekizumab 85/100GLP-1 increases natural testosterone levels via fat loss 80/100Reduced risk of joint pain 70/100Treatment of osteoarthritis 65/100Strengthens immunity 60/100

Cancer / tumor (5)

Tirzepatide does not increase overall or specific cancer risk 95/100Does not increase overall cancer risk over 26 to 72 weeks of use 95/100Does not increase the risk of specific cancer types 95/10010-mg tirzepatide dose associated with lower risk of any cancer compared to placebo 90/10010-mg dose associated with a lower risk of any cancer compared to placebo 85/100

Sleep & circadian (5)

Improves sleep 95/100· 3 srcReduction of breathing disruptions 90/100Achieves remission or mild OSA with resolution of symptoms 90/100Remission or mild OSA with no symptoms 90/100Reduction in Apnea/Hypopnea Index 85/100

Antimicrobial & antiviral (5)

Treatment of nonalcoholic steatohepatitis 90/100Resolution of Steatohepatitis without Worsening Fibrosis 85/100Supports liver health 85/100Clesrovimab-cfor prevents RSV lower respiratory tract disease 85/100Ivermectin reduces malaria transmission by 26% 70/100

Performance & recovery (5)

GLP-1 receptor agonists impact objective physical activity in adults 90/100· 2 srcLean Mass Preservation 80/100· 2 srcImproves physical functioning 90/100achieve OSA remission in some patients when combined with reduced calorie intake and exercise 88/100Extended stability and receptor exposure via molecular engineering 85/100

Skin, hair & cosmetic (5)

Dupilumab treats bullous pemphigoid 85/100Hair regrowth 72/100Restores facial volume and reduces dark circles 72/100Cosmetic claims 70/100Rezpegaldesleukin treats atopic dermatitis 70/100

Anti-fibrotic (4)

NASH resolution without worsening fibrosis 90/100MASH resolution without worsening of fibrosis 88/100At least one-stage fibrosis improvement without worsening of MASH 85/100Tirzepatide achieves NASH resolution without worsening fibrosis 85/100

Anti-inflammatory (3)

Reduces inflammation 90/100· 2 srcReduction of inflammatory markers 90/100Reduction of inflammatory cytokines 75/100

Energy & mitochondrial (3)

Boosts energy 85/100Metabolic support via NAD+ precursor 75/100Reduction of fatigue 70/100

Other Benefits (7)

Treatment of Heart Failure 95/100Visceral fat reduction via Tesamorelin 90/100Reduces breathing interruptions by 25 events per hour 90/100Sustained improvements in quality of life 85/100Zoliflodacin treats uncomplicated gonorrhea 85/100Better Tolerability for Some Users 85/100Boosts collagen production 70/100

How People Use It

Under the skin

  • 15 mg — Chronic weight management / type 2 diabetes
  • Immediate-release: 500 mg twice daily or 850 mg once daily with meals. Extended-release: 500 to 2000 mg once daily with an evening meal

For research purposes only. Not medical advice. Talk to a doctor before use.

Get Tirzepatide for Your Research

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Find Tirzepatide Research Suppliers
Tested purity COA available Fast shipping
Technical Details & Research (click to expand)

Mechanism of Action

Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 receptors. It increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite, producing substantial weight loss and glycemic improvement. Approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management).

Known Side Effects

All Dosing Protocols

Zepbound / Mounjaro chronic management (FDA-approved) — SubQ · 15 mg 92/100
Tirzepatide — SubQ 95/100

Research Citations (310)

  • Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)

    RCT2022 Key study 95/100
    Source

  • SURPASS-1: Efficacy and Safety of a Novel Dual GIP/GLP-1 Receptor Agonist

    RCT2021 93/100
    Source

  • Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.

    MetaAnalysis2022 88/100
    Source

  • Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes

    2025 95/100
    Source

  • Glucagon-like peptide 1 (GLP-1)

    2019 95/100
    Source

  • Incretin hormones: Their role in health and disease

    2018 95/100
    Source

  • Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics

    2024 95/100
    Source

  • GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art

    2021 95/100
    Source

  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

    2016 95/100
    Source

  • Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

    2019 95/100
    Source

  • Incretin hormones and type 2 diabetes

    2023 95/100
    Source

  • Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction

    2022 95/100
    Source

  • Glucose-dependent insulinotropic polypeptide (GIP)

    2025 95/100
    Source

  • LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

    2018 95/100
    Source

  • Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist

    2020 95/100
    Source

History & Milestones

Key moments in Tirzepatide’s research and regulatory timeline — sourced and dated.

  1. GLP-1R-GIPR-PPARα/γ/δ quintuple agonism corrects obesity and diabetes in micePublicationJan 1, 2026
    95/100↗ source
  2. Global glucagon-like peptide-2 receptor activation linked to increased obesity risk in the UK BiobankPublicationJan 1, 2026
    95/100↗ source
  3. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 DiabetesPublicationJan 1, 2025
    95/100↗ source
  4. Glucose-dependent insulinotropic polypeptide (GIP)PublicationJan 1, 2025
    95/100↗ source
  5. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trialPublicationJan 1, 2025
    95/100↗ source
  6. Safety and Efficacy of Obicetrapib in Patients at High Cardiovascular RiskPublicationJan 1, 2025
    90/100↗ source
  7. Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical modelsPublicationJan 1, 2025
    90/100↗ source
  8. β Cell Gαs signaling is critical for physiological and pharmacological enhancement of insulin secretionPublicationJan 1, 2025
    95/100↗ source
  9. Tirzepatide for Heart Failure with Preserved Ejection Fraction and ObesityPublicationJan 1, 2025
    95/100↗ source
  10. Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a)PublicationJan 1, 2025
    90/100↗ source
  11. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trialPublicationJan 1, 2024
    95/100↗ source
  12. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristicsPublicationJan 1, 2024
    95/100↗ source
  13. Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The SHASTA-2 Randomized Clinical TrialPublicationJan 1, 2024
    90/100↗ source
  14. The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipronPublicationJan 1, 2024
    95/100↗ source
  15. GLP-1-directed NMDA receptor antagonism for obesity treatmentPublicationJan 1, 2024
    95/100↗ source
  16. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapyPublicationJan 1, 2024
    95/100↗ source
  17. GLP-1 and GIP agonism has no direct actions in human hepatocytes or hepatic stellate cellsPublicationJan 1, 2024
    95/100↗ source
  18. Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trialPublicationJan 1, 2024
    95/100↗ source
  19. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participantsPublicationJan 1, 2024
    95/100↗ source
  20. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trialPublicationJan 1, 2024
    95/100↗ source
  21. Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trialPublicationJan 1, 2024
    95/100↗ source
  22. Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trialsPublicationJan 1, 2024
    95/100↗ source
  23. Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesPublicationJan 1, 2023
    95/100↗ source
  24. Incretin hormones and type 2 diabetesPublicationJan 1, 2023
    95/100↗ source
  25. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss-chemistry, physiology, and clinical applicationsPublicationJan 1, 2023
    95/100↗ source
  26. The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human isletsPublicationJan 1, 2023
    95/100↗ source
  27. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant PatientsPublicationJan 1, 2023
    95/100↗ source
  28. Phase 2 Trial of Baxdrostat for Treatment-Resistant HypertensionPublicationJan 1, 2023
    90/100↗ source
  29. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participantsPublicationJan 1, 2023
    95/100↗ source
  30. Glucose-dependent insulinotropic polypeptide regulates body weight and food intake via GABAergic neurons in micePublicationJan 1, 2023
    95/100↗ source
  31. Biased GLP-2 agonist with strong G protein-coupling but impaired arrestin recruitment and receptor desensitization enhances intestinal growth in micePublicationJan 1, 2023
    95/100↗ source
  32. Tirzepatide, a Dual GIP/GLP-1 Receptor Co-agonistPublicationJan 1, 2022
    88/100↗ source
  33. Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reductionPublicationJan 1, 2022
    95/100↗ source
  34. The past, present, and future physiology and pharmacology of glucagonPublicationJan 1, 2022
    95/100↗ source
  35. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trialPublicationJan 1, 2022
    95/100↗ source
  36. Tirzepatide as an Insulin SensitizerPublicationJan 1, 2022
    95/100↗ source
  37. Coronary Atherosclerotic Plaque Regression: JACC State-of-the-Art ReviewPublicationJan 1, 2022
    90/100↗ source
  38. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysisPublicationJan 1, 2022
    92/100↗ source
  39. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trialPublicationJan 1, 2022
    88/100↗ source
  40. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of conceptPublicationJan 1, 2022
    95/100↗ source
  41. Structural determinants of dual incretin receptor agonism by tirzepatidePublicationJan 1, 2022
    95/100↗ source
  42. Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese micePublicationJan 1, 2022
    95/100↗ source
  43. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systemsPublicationJan 1, 2022
    95/100↗ source
  44. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-artPublicationJan 1, 2021
    95/100↗ source
  45. Empagliflozin in Heart Failure with a Preserved Ejection FractionPublicationJan 1, 2021
    95/100↗ source
  46. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trialPublicationJan 1, 2021
    95/100↗ source
  47. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese micePublicationJan 1, 2021
    90/100↗ source
  48. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonistPublicationJan 1, 2020
    95/100↗ source
  49. Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailurePublicationJan 1, 2020
    95/100↗ source
  50. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insightsPublicationJan 1, 2020
    90/100↗ source
  51. How May GIP Enhance the Therapeutic Efficacy of GLP-1?PublicationJan 1, 2020
    95/100↗ source
  52. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonistPublicationJan 1, 2020
    95/100↗ source
  53. Molecular interactions of full-length and truncated GIP peptides with the GIP receptor - A comprehensive reviewPublicationJan 1, 2020
    95/100↗ source
  54. Glucagon-like peptide 1 (GLP-1)PublicationJan 1, 2019
    95/100↗ source
  55. Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesPublicationJan 1, 2019
    95/100↗ source
  56. Neuromedin U Does Not Act as a Decretin in RatsPublicationJan 1, 2019
    95/100↗ source
  57. Incretin hormones: Their role in health and diseasePublicationJan 1, 2018
    95/100↗ source
  58. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of conceptPublicationJan 1, 2018
    95/100↗ source
  59. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)PublicationJan 1, 2018
    90/100↗ source
  60. Oxyntomodulin: Actions and role in diabetesPublicationJan 1, 2018
    95/100↗ source
  61. Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agentsPublicationJan 1, 2018
    95/100↗ source
  62. Insulin Secretion Depends on Intra-islet Glucagon SignalingPublicationJan 1, 2018
    95/100↗ source
  63. Liraglutide and Cardiovascular Outcomes in Type 2 DiabetesPublicationJan 1, 2016
    95/100↗ source
  64. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and diseasePublicationJan 1, 2015
    95/100↗ source

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, dosing at a glance, and what the research says — one page, one email.

No spam. Unsubscribe anytime.

Related on The Health Stacks

Explore by goal

GLP-1 & Metabolic Peptides

Related peptides

SemaglutideRetatrutideMOTS-c

Compare

Tirzepatide vs Semaglutide Tirzepatide vs Retatrutide